Clinago - English - Clinago

Do you have atopic dermatitis that is difficult to control?

Atopic dermatitis (AD), the most common form of eczema, is a chronic inflammatory skin condition that affects individuals of all ages, ethnicities, and geographic regions worldwide.

We are currently recruiting participants aged 18 to 70 years with moderate to severe atopic dermatitis (Eczema) to take part in a research study. Individuals whose symptoms are widespread, cause significant itch, affect sleep, or are not adequately controlled by their current treatment may qualify.

Compensation for time and travel may be available. There will be no cost to you for being considered or for participating in this study, and you will be provided with all study medication, examinations, and medical care related to the study.

Join the trial to contribute to the research of this treatment for AD.

Visits

Total

Length

Study Length

Total

Up to 20 visits over approximately 16 months

Length

2.5 to 4 hours

Study Length

Up to 5 weeks of screening period, up to 48 weeks of treatment and approximately 16 weeks of follow up period, with the possibility to be invited to participate in a separate long-term extension study

Summary

This study is being done to test how safe is the study drug and how well it relives the signs and symptoms of your atopic dermatitis. The study drug, which is called IMG-007, is given as an injection under the skin by a healthcare professional.